Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB)
· seekingalpha.com
Solid Biosciences is leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. Learn more about SLDB stock here.
I last covered Solid Biosciences Inc. ( SLDB ) nearly three months ago, focusing on its broader rare-disease pipeline. Since then, Solid has reported $377.7 mil...